Drugs / SK-09
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07267026 | Dec 2025 → Oct 2026 expected | focal segmental glomerulosclerosis | Consun Pharmaceutical Group | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SK-09 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07267026 ↗ |
| Route | Oral | “single oral doses of SK-09 tablets” NCT07267026 ↗ |